Best practice

Full on-patent portfolio for HIV/AIDS and viral hepatitis now under voluntary licences

With the most non-exclusive voluntary licences for patented products, Gilead has licensed its entire patented portfolio for HIV/AIDS and viral hepatitis (HBV/HCV)

Explore further

How we measure

How we measure

The Index evaluates pharmaceutical companies in areas where they have the biggest potential and responsibility to make change, such as R&D and pricing. Find out more about the analytical framework and areas of evaluation.

Get in touch

Back to top |